RS Investment Management’s Amicus Therapeutics FOLD Stock Holding History

RS Investment Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$18.7M	Sell	3,429,187 -98,516	-3%	-$689K	0.19%	188
2016 Q1	$29.8M	Buy	3,527,703 +38,840	+1%	+$275K	0.29%	124
2015 Q4	$33.8M	Buy	3,488,863 +628,438	+22%	+$5.66M	0.3%	113
2015 Q3	$40M	Buy	2,860,425 +173,360	+6%	+$2.72M	0.36%	103
2015 Q2	$38M	Buy	2,687,065 +122,520	+5%	+$1.47M	0.33%	111
2015 Q1	$27.9M	Sell	2,564,545 -286,410	-10%	-$2.52M	0.25%	151
2014 Q4	$23.7M	Buy	2,850,955 +1,602,740	+128%	+$11M	0.21%	168
2014 Q3	$7.43M	Buy	+1,248,215	New	+$6.54M	0.07%	265
2014 Q2	–	Sell	-2,816,739	Closed	-$5.83M	–	384
2014 Q1	$5.83M	Buy	2,816,739 +19,400	+0.7%	+$48.5K	0.03%	261
2013 Q4	$6.57M	Buy	2,797,339 +2,900	+0.1%	+$6.37K	0.04%	241
2013 Q3	$6.48M	Buy	2,794,439 +272,020	+11%	+$683K	0.04%	229
2013 Q2	$5.88M	Buy	+2,522,419	New	+$7.75M	0.04%	231

Other funds holding FOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

RS Investment Management's FOLD Position: Q2 2016 in Review

RS Investment Management reduced its Amicus Therapeutics (FOLD) stake by 2.8% in Q2 2016, selling an estimated $689K and leaving 3,429,187 shares worth $18.7M. The position accounts for 0.19% of the portfolio, ranked #188.

RS Investment Management first reported a position in FOLD in Q2 2013 and has held it in 12 quarters since. The position peaked at $40M in Q3 2015. 130 funds tracked by Wall St. Rank hold FOLD as of Q2 2016.

RS Investment Management held 3,429,187 shares of Amicus Therapeutics worth $18.7M as of Q2 2016.
RS Investment Management sold 98,516 Amicus Therapeutics shares in Q2 2016, an estimated $689K.
Amicus Therapeutics made up 0.19% of RS Investment Management's portfolio in Q2 2016, its #188 holding.
RS Investment Management first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 12 quarters since.
RS Investment Management's Amicus Therapeutics position peaked at $40M in Q3 2015.
130 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2016.

Based on RS Investment Management's 13F filing for Q2 2016, filed 26 Jul 2016.